As part of the medium-term management plan capital policy, the Company will acquire treasury stock (up to 1,250,000 shares, 4.4%) and cancel those shares on May 31, 2027. Acquisition period: 2026\/10\/15\u20132027\/5\/21; total amount upper limit: 2,000 million yen.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4577","jir_company_name":"Daito Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-10-14","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/4577-20261014-03.pdf","jir_short_summary":"As part of the medium-term management plan capital policy, the Company will acquire treasury stock (up to 1,250,000 shares, 4.4%) and cancel those shares on May 31, 2027. Acquisition period: 2026\/10\/15\u20132027\/5\/21; total amount upper limit: 2,000 million yen.","jir_summary":"### Details of Capital Policy Implementation\nAs part of the medium-term management plan, the Company will carry out treasury stock acquisition and cancellation. The acquisition is up to 1,250,000 shares (representing 4.4% of the total number of issued shares), with a total amount upper limit of 2,000 million yen. The acquisition period is from October 15, 2026 to May 21, 2027, and the trading method is the Tokyo Stock Exchange on-floor market. The Company plans to cancel the same number of shares, 1,250,000 shares, with the cancellation date set as May 31, 2027.\n\n### Impact and Future Outlook\nThrough the acquisition and cancellation of treasury stock, the Company intends to enhance shareholder returns and capital efficiency. As of September 30, 2026, the current treasury stock holding is slightly under 500,000 shares. Through this acquisition and cancellation, the Company aims to suppress dilution and maximize shareholder value.","jir_financial_highlights":"Total number of treasury shares to be acquired: 1,250,000 shares (Upper limit)\nTotal acquisition amount for treasury shares: 2,000 million yen (Upper limit)\nTotal number of treasury shares to be cancelled: 1,250,000 shares (Planned)\nScheduled cancellation date: 2027-05-31","jir_category":"","jir_hashtags":"#DaitoPharmaceutical, #TreasuryStockAcquisition, #CapitalPolicy","jir_key_figures":"Total number of treasury shares to be acquired: 1,250,000 shares (upper limit)\nTotal acquisition amount for treasury shares: 2,000 million yen (upper limit)\nTotal number of shares to be cancelled: 1,250,000 shares (planned)","jir_meta_title":"Daito Pharmaceutical Co., Ltd. Announces Treasury Stock Acquisition and Cancellation | October 2026","jir_meta_description":"Daito Pharmaceutical Co., Ltd. announces a treasury stock acquisition and cancellation as part of its medium-term management plan. Acquisition upper limit: 1,250,000 shares; total amount: 2,000 million yen; acquisition period: 2026\/10\/15\u20132027\/5\/21; cancellation scheduled for 2027\/5\/31. Aimed at enhancing shareholder returns and capital efficiency.","jir_og_title":"Daito Pharmaceutical Co., Ltd. Announces Treasury Stock Acquisition and Cancellation","jir_og_description":"As part of the medium-term management plan, the Company will acquire up to 1,250,000 shares (total amount up to 2,000 million yen) between 2026\/10\/15 and 2027\/5\/21. Cancellation is scheduled for 2027\/5\/31. The initiative aims to enhance shareholder returns and capital efficiency.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":56861,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"share_buyback","footnotes":""},"sector":[],"importance":[],"class_list":["post-130520","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n